These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21404058)

  • 1. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis.
    Rao B; Gao Y; Huang J; Gao X; Fu X; Huang M; Yao J; Wang J; Li W; Zhang J; Liu H; Wang L; Wang J
    Int J Colorectal Dis; 2011 May; 26(5):593-601. PubMed ID: 21404058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.
    Ines C; Donia O; Rahma B; Ben Ammar A; Sameh A; Khalfallah T; Abdelmajid BH; Sabeh M; Saadia B
    Tumour Biol; 2014 Jul; 35(7):7163-75. PubMed ID: 24763823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians.
    Malhotra P; Anwar M; Nanda N; Kochhar R; Wig JD; Vaiphei K; Mahmood S
    Tumour Biol; 2013 Jun; 34(3):1901-11. PubMed ID: 23526092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical Role of p53 and K-ras in the Diagnosis of Early Colorectal Cancer: a One-year, Single-center Analysis.
    Lu HY; Lin RT; Zhou GX; Yu TM; Liu ZJ
    Int J Med Sci; 2017; 14(11):1154-1162. PubMed ID: 29104470
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
    Russo A; Bazan V; Agnese V; Rodolico V; Gebbia N
    Ann Oncol; 2005 May; 16 Suppl 4():iv44-49. PubMed ID: 15923428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer.
    Schimanski CC; Moehler M; Gockel I; Zimmermann T; Lang H; Galle PR; Berger MR
    J Cancer Res Clin Oncol; 2011 Jul; 137(7):1139-45. PubMed ID: 21468700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
    Tentler JJ; Nallapareddy S; Tan AC; Spreafico A; Pitts TM; Morelli MP; Selby HM; Kachaeva MI; Flanigan SA; Kulikowski GN; Leong S; Arcaroli JJ; Messersmith WA; Eckhardt SG
    Mol Cancer Ther; 2010 Dec; 9(12):3351-62. PubMed ID: 20923857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p73 Isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis.
    Díaz R; Peña C; Silva J; Lorenzo Y; García V; García JM; Sánchez A; Espinosa P; Yuste R; Bonilla F; Domínguez G
    Int J Cancer; 2008 Sep; 123(5):1060-7. PubMed ID: 18546269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
    J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
    Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
    Ince WL; Jubb AM; Holden SN; Holmgren EB; Tobin P; Sridhar M; Hurwitz HI; Kabbinavar F; Novotny WF; Hillan KJ; Koeppen H
    J Natl Cancer Inst; 2005 Jul; 97(13):981-9. PubMed ID: 15998951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review.
    Rui YY; Zhang D; Zhou ZG; Wang C; Yang L; Yu YY; Chen HN
    PLoS One; 2013; 8(10):e77901. PubMed ID: 24205021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A gene marker panel covering the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans.
    Scholtka B; Schneider M; Melcher R; Katzenberger T; Friedrich D; Berghof-Jäger K; Scheppach W; Steinberg P
    Cancer Epidemiol; 2009 Aug; 33(2):123-9. PubMed ID: 19679059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
    Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
    Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
    Bazan V; Agnese V; Corsale S; Calò V; Valerio MR; Latteri MA; Vieni S; Grassi N; Cicero G; Dardanoni G; Tomasino RM; Colucci G; Gebbia N; Russo A;
    Ann Oncol; 2005 May; 16 Suppl 4():iv50-55. PubMed ID: 15923430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P21WAF1/CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis.
    Mitomi H; Ohkura Y; Fukui N; Kanazawa H; Kishimoto I; Nakamura T; Yokoyama K; Sada M; Kobayashi K; Tanabe S; Saigenji K
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):883-9. PubMed ID: 17873613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
    Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
    Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome.
    Flanagan L; Schmid J; Ebert M; Soucek P; Kunicka T; Liska V; Bruha J; Neary P; Dezeeuw N; Tommasino M; Jenab M; Prehn JH; Hughes DJ
    Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1381-90. PubMed ID: 24599709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.